<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Tacni" /><meta name="IX" content="Tacni" /><title>Tacni®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5644-tacni.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5644-tacni.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5644-tacni.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="PHP5614-corticosteroids-and-other-immunosuppressants.htm">8.2.2 Corticosteroids and other immunosuppressants</a> &gt; <a href="PHP5639-tacrolimus.htm">TACROLIMUS</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5637-sirolimus.htm" title="Previous: SIROLIMUS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm" title="Next: 8.2.3 Anti-lymphocyte monoclonal antibodies">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301040.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus (Topical)</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Skin and Mucous Membrane Agents 84:00 &gt; Skin and Mucous Membrane Agents, Miscellaneous 84:92</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a395035.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Immunosuppressive Agents 92:44</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/4992-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tacrolimus</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Tacrolimus</p></div></li></ul><ul><li><h3>British National Formulary (6)</h3></li><li><a href="PHP5614-corticosteroids-and-other-immunosuppressants.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.2 Corticosteroids and other immunosuppressants</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="PHP5639-tacrolimus.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">TACROLIMUS</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.2 Corticosteroids and other immunosuppressants</p></div></li><li><a href="PHP7766-drugs-affecting-the-immune-response.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">13.5.3 Drugs affecting the immune response</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 13 Skin &gt; 13.5 Preparations for eczema and psoriasis</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22tacrolimus%22%22tacrolimus%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (6)</a></li></ul><ul><li><h3>BNF for Children (7)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13833-corticosteroids-and-other-immunosuppressants.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.2 Corticosteroids and other immunosuppressants</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13847-tacrolimus.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">TACROLIMUS</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.2 Corticosteroids and other immunosuppressants</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13850-modigraf.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Modigraf®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.2 Corticosteroids and other immunosuppressants &gt; TACROLIMUS</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22tacrolimus%22%22tacrolimus%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (7)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1557.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a595003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0019s0008.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/t01-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/4992-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Immunosuppressants &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09025.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-T2.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus Hydrate</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; T</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D123.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tacrolimus</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Drug Administration via Enteral Feeding Tubes</h3></li><li><a href="http://www.medicinescomplete.com/mc/tubes/2010/c352.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Drug Administration via Enteral Feeding Tubes</strong> &gt; Handbook of Drug Administration via Enteral Feeding Tubes &gt; Monographs &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>TACROLIMUS</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int730-tacrolimus.htm">Tacrolimus</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">prophylaxis of organ rejection in liver, kidney, and heart allograft recipients and allograft rejection resistant to conventional immunosuppressive regimens, see also notes above; moderate to severe atopic eczema (section 13.5.3)</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">monitor blood pressure, ECG (<strong>important:</strong> see Cardiomyopathy below), fasting blood-glucose concentration, haematological and neurological (including visual) parameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration (especially during episodes of diarrhoea)—consult local treatment protocol for details; QT-interval prolongation; neurotoxicity; increased risk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; <strong>interactions:</strong> Appendix 1 (tacrolimus)</p></div><div class="cG"><div class="cE"><h3 class="cT">Driving</h3> <p class="cT">May affect performance of skilled tasks (e.g. driving)</p></div></div></div><div class="cL"><div class="cE"><h2 class="cN">Contra-indications </h2> <p class="cT">hypersensitivity to macrolides; avoid concurrent administration with ciclosporin (care if patient has previously received ciclosporin)</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Hepatic impairment </h2> <p class="cT">dose reduction may be necessary in severe impairment</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">exclude before treatment; avoid unless potential benefit outweighs risk—risk of premature delivery, intra-uterine growth restriction, and hyperkalaemia; toxicity in <em>animal</em> studies</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">avoid—present in breast milk</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">nausea, vomiting, diarrhoea, constipation, dyspepsia, flatulence, bloating, weight changes, anorexia, gastro-intestinal inflammation, ulceration, and perforation, hepatic dysfunction, jaundice, cholestasis, ascites, bile-duct abnormalities, oedema, tachycardia, hypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea, pleural effusion, parenchymal lung disorders, sleep disturbances, tremor, headache, peripheral neuropathy, mood changes, depression, confusion, anxiety, psychosis, seizures, paraesthesia, dizziness, renal impairment, renal failure, renal tubular necrosis, urinary abnormalities, hyperglycaemia, electrolyte disturbances (including hyperkalaemia, hypokalaemia, and hyperuricaemia), blood disorders (including anaemia, leucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle cramp, visual disturbances, photophobia, tinnitus, impaired hearing, alopecia, sweating, acne; <em>less commonly</em> paralytic ileus, gastro-intestinal reflux disease, peritonitis, pancreatitis, heart failure, arrhythmia, cardiac arrest, cerebrovascular accident, cardiomyopathy (<strong>important</strong>: see Cardiomyopathy below), palpitation, respiratory failure, coma, speech disorder, amnesia, paralysis, influenza-like symptoms, encephalopathy, coagulation disorders, photosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia, dermatitis; <em>rarely</em> pericardial effusion, respiratory distress syndrome, posterior reversible encephalopathy syndrome, dehydration, thrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis, hirsutism; <em>very rarely</em> myasthenia, haemorrhagic cystitis, Stevens-Johnson syndrome; <em>also reported</em> pure red cell aplasia, agranulocytosis, haemolytic anaemia</p></div><div class="cG"><div class="cE"><h3 class="cT">Cardiomyopathy</h3> <p class="cT">Cardiomyopathy has been reported in children. Patients should be monitored by echocardiography for hypertrophic changes—consider dose reduction or discontinuation if these occur</p></div></div></div><div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p>See under preparations</p></li></ul></div></div><div class="cI" id="PHP5640"><p class="cAE">MHRA/CHM advice</p><h3 class="cT">Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)</h3><p>Inadvertent switching between oral tacrolimus products has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only. </p><p>There are 3 different oral formulations of tacrolimus:</p><ul><li><p><em>Adoport</em>®, <em>Prograf</em>®, <em>Capexion</em>®, <em>Tacni</em>®, and <em>Vivadex</em>® are immediate-release capsules that are taken twice daily, once in the morning and once in the evening;</p> </li><li><p><em>Modigraf</em>® granules are used to prepare an immediate-release oral suspension which is taken twice daily, once in the morning and once in the evening;</p> </li><li><p><em>Advagraf</em>® is a prolonged-release capsule that is taken once daily in the morning.</p> </li></ul><p>Switching between different oral formulations of tacrolimus requires careful supervision and therapeutic monitoring by an appropriate specialist.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP5641-adoport.htm#PHP5641-adoport" title="Adoport®">Adoport®</a></li><li><a href="PHP18397-capexion.htm#PHP18397-capexion" title="Capexion®">Capexion®</a></li><li><a href="PHP5642-modigraf.htm#PHP5642-modigraf" title="Modigraf®">Modigraf®</a></li><li><a href="PHP5643-prograf.htm#PHP5643-prograf" title="Prograf®">Prograf®</a></li></ul><div id="PHP5644-tacni" style="margin: 0 0 0 20px;"><h1 class="title">Tacni® <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10365">TEVA UK</a>)</span><span> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Capsules</strong>, tacrolimus 500 micrograms (ivory), net price 50-cap pack = £50.48; 1 mg (white), 50-cap pack = £65.49, 100-cap pack = £130.99; 5 mg (red), 50-cap pack = £242.01. Label: 23, counselling, driving</p><div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Tacrolimus is incompatible with PVC</p></div></div><p class="cR"><strong>Dose </strong>liver transplantation, starting 12 hours after transplantation, <span class="cK">by mouth</span>, 100–200 micrograms/kg daily in 2 divided doses; <span class="cP">child</span> 300 micrograms/kg daily in 2 divided doses</p> <p class="cR">Renal transplantation, starting within 24 hours of transplantation, <span class="cK">by mouth</span>, 200–300 micrograms/kg daily in 2 divided doses; <span class="cP">child</span> 300 micrograms/kg daily in 2 divided doses</p> <p class="cR">Heart transplantation with antibody induction (starting within 5 days of transplantation) or without antibody induction (starting within 12 hours of transplantation), <span class="cK">by mouth</span>, 75 micrograms/kg daily in 2 divided doses; <span class="cP">child</span> with antibody induction (starting within 5 days of transplantation), 100–300 micrograms/kg daily in 2 divided doses; without antibody induction (starting within 12 hours of transplantation), 300 micrograms/kg daily in 2 divided doses as soon as clinically possible (8–12 hours after discontinuing intravenous infusion)</p> <p class="cR">Maintenance treatment, dose adjusted according to response and whole blood concentration</p> <p class="cR">Rejection therapy, seek specialist advice</p> </div></div><ul class="jT"><li><a href="PHP5645-vivadex.htm#PHP5645-vivadex" title="Vivadex®">Vivadex®</a></li><li id="_PHP5646-modified-release_PHP5646-modified-release"><a href="PHP5646-modified-release.htm#PHP5646-modified-release" title="Modified release">Modified release</a><ul style="display: none"><li><a href="PHP5647-advagraf.htm#PHP5647-advagraf" title="Advagraf®">Advagraf®</a></li></ul></li><li><a href="PHP5648-tacrolimus-formulations-unlicensed.htm#PHP5648-tacrolimus-formulations-unlicensed" title="Tacrolimus formulations [unlicensed]">Tacrolimus formulations [unlicensed]</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5637-sirolimus.htm">Previous: SIROLIMUS</a> | <a class="top" href="PHP5644-tacni.htm#">Top</a> | <a accesskey="]" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm">Next: 8.2.3 Anti-lymphocyte monoclonal antibodies</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>